Inveready

Inveready is a Spanish investment firm headquartered in San Sebastian with a hybrid strategy that combines venture equity and venture debt across the life sciences and technology spectrum. Healthcare focus includes biotech and medical devices, where the firm uses non-dilutive structures alongside equity to fund capital-intensive operations. There is no explicit artificial intelligence thesis, although the broader platform spans digital businesses where AI components may appear. Limited public information is available about individually named partners attached to specific healthcare deals beyond Inveready’s general disclosures, though the firm is recognized among Iberian institutional investors.

Inveready engages across the full life cycle from Seed through Series C and growth, with check sizes typically in the one to five million dollar range and the ability to layer venture debt facilities on top of equity. Geographic concentration is Spain, with selective participation in European life sciences syndicates and occasional transatlantic exposure. The firm participates in primary rounds and provides structured debt to companies that have already raised institutional equity, making it relevant at multiple points in a company’s financing history rather than a single entry stage.

For founders, Inveready is particularly useful when building biotech or medical device businesses that need to extend runway between equity rounds without taking severe dilution, or when assembling a Spanish-led syndicate for a primary round. Diligence focuses on cash burn, milestone planning, intellectual property, and the path to commercial or clinical inflection points that justify additional capital. Founders should expect a quantitative, finance-led process that evaluates how equity and debt fit together, and should arrive prepared with detailed capital plans, scenario analysis, and clarity on how non-dilutive instruments would serve specific operating needs.